Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Luckily for you, we at StockStory have no conflicts of interest - our sole job is to help you find genuinely promising companies. That said, here is one stock where Wall Street’s excitement appears well-founded and two where analysts may be overlooking some important risks.
Two Stocks to Sell:
Sprinklr (CXM)
Consensus Price Target: $7.88 (56.3% implied return)
With a proprietary AI engine processing 450 million data points daily across 30+ digital channels, Sprinklr (NYSE: CXM) provides cloud-based software that helps large enterprises manage customer experiences across social, messaging, chat, and voice channels.
Why Is CXM Risky?
- Customers had second thoughts about committing to its platform over the last year as its average billings growth of 5.3% underwhelmed
- Demand will likely fall over the next 12 months as Wall Street expects flat revenue
- Operating profits increased over the last year as the company gained some leverage on its fixed costs and became more efficient
At $5.04 per share, Sprinklr trades at 1.4x forward price-to-sales. Dive into our free research report to see why there are better opportunities than CXM.
IQVIA (IQV)
Consensus Price Target: $226.95 (35.1% implied return)
Created from the 2016 merger of Quintiles (a clinical research organization) and IMS Health (a healthcare data specialist), IQVIA (NYSE: IQV) provides clinical research services, data analytics, and technology solutions to help pharmaceutical companies develop and market medications more effectively.
Why Does IQV Give Us Pause?
- The company has faced growth challenges as its 5.1% annual revenue increases over the last two years fell short of other healthcare companies
- Constant currency revenue growth has disappointed over the past two years and shows demand was soft
- Free cash flow margin has stayed in place over the last five years
IQVIA’s stock price of $168 implies a valuation ratio of 12.8x forward P/E. Read our free research report to see why you should think twice about including IQV in your portfolio.
One Stock to Buy:
Nextpower (NXT)
Consensus Price Target: $150.19 (20.2% implied return)
With its technology playing a key role in the massive 1.2 gigawatt Noor Abu Dhabi solar farm project, Nextpower (NASDAQ: NXT) is a provider of solar tracker systems that help solar panels follow the sun.
Why Is NXT a Top Pick?
- Annual revenue growth of 19.3% over the last two years was superb and indicates its market share increased during this cycle
- Free cash flow margin jumped by 25.3 percentage points over the last five years, giving the company more resources to pursue growth initiatives, repurchase shares, or pay dividends
- Improving returns on capital reflect management’s ability to monetize investments
Nextpower is trading at $125 per share, or 27x forward P/E. Is now the right time to buy? See for yourself in our in-depth research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
